Jeremy Grantham Vertex Pharmaceuticals Inc Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $11.8 Million - $13.2 Million	-37,394 Reduced 38.99%	58,506 $20.6 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $6.03 Million - $6.88 Million	-21,300 Reduced 18.17%	95,900 $30.2 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $1.2 Million - $1.35 Million	4,200 Added 3.72%	117,200 $33.8 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $136,915 - $152,765	-500 Reduced 0.44%	113,000 $32.7 Million
Q2 2022 Aug 12, 2022	BUY	$234.96 - $292.55 $7.38 Million - $9.19 Million	31,400 Added 38.25%	113,500 $32 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $18.2 Million - $21.4 Million	82,100 New	82,100 $21.4 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $526,752 - $609,184	-3,200 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $486,112 - $615,072	3,200 New	3,200 $530,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.